FDA Brief

Warning letters Drugs

FDA warning letter to

Chem-Tech, Ltd.

High riskIssued Feb 11, 2025Posted Mar 4, 2025Center for Drug Evaluation and Research (CDER)

Chem-Tech, Ltd. lacked adequate investigations and clean equipment for its OTC drug.

What happened

FDA inspected Chem-Tech’s drug manufacturing facility in Pleasantville, IA, from September 17 to 20, 2024. It found inadequate investigations of out-of-specification (OOS) assay results, unsanitary mixing and filling areas, and inadequate quality unit procedures, all cited as current good manufacturing practice (CGMP) violations. FDA also said Chem-Tech’s October 11, 2024, response lacked supporting documentation and evidence of corrective actions.

What FDA found

  1. Chem-Tech did not thoroughly investigate out-of-specification assay results or unexplained batch failures, did not determine root causes, and released reworked batches without adequate corrective and preventive actions (CAPA).

    21 CFR 211.192
  2. Chem-Tech lacked scientifically supported mixing process validation and finished-product hold-time studies; its validation covered only filling and hold times were changed without supporting data.

    21 CFR 211.110(a)
  3. Chem-Tech did not keep equipment clean and maintained; investigators saw dirt and a dead insect on a mixing tank lid, leftover product and discoloration in the tank, and no validated cleaning procedure.

    21 CFR 211.67(a) and (b)
  4. Chem-Tech lacked a preventive maintenance program with procedures, and the meter used to add potable water to the drug product had never been calibrated.

    21 CFR 211.67(a) and (b)
  5. Chem-Tech’s quality unit lacked procedures for GMP training, OOS handling, and change management, and its deviation and complaint procedures were inadequate.

    21 CFR 211.22(d)

What FDA wants

FDA asks Chem-Tech to respond in writing within 15 working days with what it has done to correct the violations and prevent recurrence, and if it cannot finish, to give reasons and a completion schedule. If it plans to resume drug manufacturing, it must notify FDA and provide a summary of remediations and CAPA.

Who should pay attention

  • brands that buy OTC drugs from contract manufacturers
  • contract manufacturers with shared mixing and filling equipment
  • quality teams handling OOS investigations, cleaning validation, and complaints

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  3. Silgan Dispensing Systems

    Silgan Unicep Packaging was cited for manufacturing quality failures and unapproved new drugs after invalidated microbial tests and a fungal recall.

    High risk
  4. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk